Miembros del Grupo
Coordinador
Investigadores
Ana
Quiroga Varela
Marta
Zamarbide González
Colaboradores
Laura
Armengou García
Arántzazu
Belloso Iguerategui
Leire
Merino Galan
Líneas de Investigación
- Alteración funcional y estructural de la sinapsis dopaminérgica en la enfermedad de Parkinson.
- Demencia y deterioro cognitivo en la enfermedad de Parkinson.
- Estimulación cerebral profunda, lesiones por HIFU (high intensity focused ultrasound) y fisiopatología de los ganglios basales en la enfermedad de Parkinson.
- Papel de la activación glial y mecanismos inflamatorios en la muerte dopaminérgica.
- Trastornos de control de impulsos en la enfermedad de Parkinson.
- Trastornos de la marcha en la enfermedad de Parkinson.
Palabras Clave
- Demencia
- Deterioro cognitivo
- Estimulación cerebral profunda
- Ganglios basales
- Glía
- HIFU
- Neuroinflamación
- Parkinson
- Sinapsis
- Trastorno de impulsividad
Publicaciones Científicas desde 2018
-
Autores: Lee, J. Y. (Autor de correspondencia); Martin Bastida, Antonio; Murueta-Goyena, A.; et al.Revista: NATURE REVIEWS NEUROLOGYISSN: 1759-4758 Vol.18 N° 4 2022 págs. 203 - 220ResumenParkinson disease (PD) is a progressive disorder characterized by dopaminergic neurodegeneration in the brain. The development of parkinsonism is preceded by a long prodromal phase, and >50% of dopaminergic neurons can be lost from the substantia nigra by the time of the initial diagnosis. Therefore, validation of in vivo imaging biomarkers for early diagnosis and monitoring of disease progression is essential for future therapeutic developments. PET and single-photon emission CT targeting the presynaptic terminals of dopaminergic neurons can be used for early diagnosis by detecting axonal degeneration in the striatum. However, these techniques poorly differentiate atypical parkinsonian syndromes from PD, and their availability is limited in clinical settings. Advanced MRI in which pathological changes in the substantia nigra are visualized with diffusion, iron-sensitive susceptibility and neuromelanin-sensitive sequences potentially represents a more accessible imaging tool. Although these techniques can visualize the classic degenerative changes in PD, they might be insufficient for phenotyping or prognostication of heterogeneous aspects of PD resulting from extranigral pathologies. The retina is an emerging imaging target owing to its pathological involvement early in PD, which correlates with brain pathology. Retinal optical coherence tomography (OCT) is a non-invasive technique to visualize structural changes in the retina. Progressive parafoveal thinning and fovea avascular zone remodelling, as revealed by OCT, provide potential biomarkers for early diagnosis and prognostication in PD. As we discuss in this Review, multimodal imaging of the substantia nigra and retina is a promising tool to aid diagnosis and management of PD. In vivo imaging biomarkers for early diagnosis and monitoring of Parkinson disease (PD) are important for the development of new therapies. The authors review recent advances in brain and retinal imaging in PD, focusing particularly on multimodal approaches with applications at the prodromal stage.
-
Autores: Dileone, M.; Ammann, C.; Catanzaro, V.; et al.Revista: BRAIN STIMULATIONISSN: 1935-861X Vol.15 N° 3 2022 págs. 857 - 860
-
Autores: Mohamed, M. A.; Zeng, Z.; Gennaro, M.; et al.Título: Astrogliosis in aging and Parkinson's disease dementia: a new clinical study with C-11-BU99008 PETRevista: BRAIN COMMUNICATIONSISSN: 2632-1297 Vol.4 N° 5 2022 págs. fcac199ResumenThis is an imaging study in Parkinson's disease dementia with C-11-BU99008 PET (experimental radioligand developed to assess astrocytic distribution in the living brain). Mohamed M. and Zeng Z et al. report that astrogliosis is common with aging in a region-specific manner. Here, C-11-BU99008 PET does not differentiate these patients from healthy controls. The role of astrogliosis in the pathology of brain aging and neurodegenerative diseases has recently drawn great attention. Imidazoline-2 binding sites represent a possible target to map the distribution of reactive astrocytes. In this study, we use C-11-BU99008, an imidazoline-2 binding sites-specific PET radioligand, to image reactive astrocytes in vivo in healthy controls and patients with established Parkinson's disease dementia. Eighteen healthy controls (age: 45-78 years) and six patients with Parkinson's disease dementia (age: 64-77 years) had one C-11-BU99008 PET-CT scan with arterial input function. All subjects underwent one 3 T MRI brain scan to facilitate the analysis of the PET data and to capture individual cerebral atrophy. Regional C-11-BU99008 volumes of distribution were calculated for each subject by the two-tissue compartmental modelling. Positive correlations between C-11-BU99008 volumes of distribution values and age were found for all tested regions across the brain within healthy controls (P < 0.05); furthermore, multiple regression indicated that aging affects C-11-BU99008 volumes of distribution values in a region-specific manner. Independent samples t-test indicated that there was no significant group difference in C-11-BU99008 volumes of distribution values between Parkinson's disease dementia (n = 6; mean age = 71.97 +/- 4.66 years) and older healthy controls (n = 9; mean age = 71.90 +/- 5.51 years). Our data set shows that astrogliosis is common with aging in a region-specific manner. However, in this set-up, C-11-BU99008 PET cannot differentiate patients with Parkinson's disease dementia from healthy controls of similar age.
-
Autores: Basaia, S.; Agosta, F.; Diez, I.; et al.Revista: NEUROIMAGE. CLINICALISSN: 2213-1582 Vol.33 2022 págs. 102941ResumenThe genetic traits that underlie vulnerability to neuronal damage across specific brain circuits in Parkinson's disease (PD) remain to be elucidated. In this study, we characterized the brain topological intersection between propagating connectivity networks in controls and PD participants and gene expression patterns across the human cortex - such as the SNCA gene. We observed that brain connectivity originated from PD-related pathology epicenters in the brainstem recapitulated the anatomical distribution of alpha-synuclein histopathology in postmortem data. We also discovered that the gene set most related to cortical propagation patterns of PDrelated pathology was primarily involved in microtubule cellular components. Thus, this study sheds light on new avenues for enhancing detection of PD neuronal vulnerability via an evaluation of in vivo connectivity trajectories across the human brain and successful integration of neuroimaging-genetic strategies.
-
Autores: Xing, Y.; Sapuan, A. H.; Martin Bastida, Antonio; et al.Revista: MOVEMENT DISORDERSISSN: 0885-3185 Vol.37 N° 5 2022 págs. 1028 - 1039ResumenBackground Clinical diagnosis and monitoring of Parkinson's disease (PD) remain challenging because of the lack of an established biomarker. Neuromelanin-magnetic resonance imaging (NM-MRI) is an emerging biomarker of nigral depigmentation indexing the loss of melanized neurons but has unknown prospective diagnostic and tracking performance in multicenter settings. Objectives The aim was to investigate the diagnostic accuracy of NM-MRI in early PD in a multiprotocol setting and to determine and compare serial NM-MRI changes in PD and controls. Methods In this longitudinal case-control 3 T MRI study, 148 patients and 97 controls were included from six UK clinical centers, of whom 140 underwent a second scan after 1.5 to 3 years. An automated template-based analysis was applied for subregional substantia nigra NM-MRI contrast and volume assessment. A point estimate of the period of prediagnostic depigmentation was computed. Results All NM metrics performed well to discriminate patients from controls, with receiver operating characteristic showing 85% accuracy for ventral NM contrast and 83% for volume. Generalizability using a priori volume cutoff was good (79% accuracy). Serial MRI demonstrated accelerated NM loss in patients compared to controls. Ventral NM contrast loss was point estimated to start 5 to 6 years before clinical diagnosis. Ventral nigral depigmentation was greater in the most affected side, more severe cases, and nigral NM volume change correlated with change in motor severity. Conclusions We demonstrate that NM-MRI provides clinically useful diagnostic information in early PD across protocols, platforms, and sites. It provides methods and estimated depigmentation rates that highlight the potential to detect preclinical PD and track progression for biomarker-enabled clinical trials. (c) 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society
-
Autores: MERINO GALAN, Leire; Jiménez-Urbieta, H.; Zamarbide González, Marta; et al.Revista: BRAINISSN: 0006-8950 Vol.145 N° 6 2022 págs. 2092 - 2107ResumenSynaptic impairment might precede neuronal degeneration in Parkinson's disease. However, the intimate mechanisms altering synaptic function by the accumulation of presynaptic alpha-synuclein in striatal dopaminergic terminals before dopaminergic death occurs, have not been elucidated. Our aim is to unravel the sequence of synaptic functional and structural changes preceding symptomatic dopaminergic cell death. As such, we evaluated the temporal sequence of functional and structural changes at striatal synapses before parkinsonian motor features appear in a rat model of progressive dopaminergic death induced by overexpression of the human mutated A53T alpha-synuclein in the substantia nigra pars compacta, a protein transported to these synapses. Sequential window acquisition of all theoretical mass spectra proteomics identified deregulated proteins involved first in energy metabolism and later, in vesicle cycling and autophagy. After protein deregulation and when alpha-synuclein accumulated at striatal synapses, alterations to mitochondrial bioenergetics were observed using a Seahorse XF96 analyser. Sustained dysfunctional mitochondrial bioenergetics was followed by a decrease in the number of dopaminergic terminals, morphological and ultrastructural alterations, and an abnormal accumulation of autophagic/endocytic vesicles inside the remaining dopaminergic fibres was evident by electron microscopy. The total mitochondrial population remained unchanged whereas the number of ultrastructurally damaged mitochondria increases as the pathological process evolved. We also observed ultrastructural signs of plasticity within glutamatergic synapses before the expression of motor abnormalities, such as a reduction in axospinous synapses and an increase in perforated postsynaptic densities. Overall, we found that a synaptic energetic failure and accumulation of dysfunctional organelles occur sequentially at the dopaminergic terminals as the earliest events preceding structural changes and cell death. We also identify key proteins involved in these earliest functional abnormalities that may be modulated and serve as therapeutic targets to counterbalance the degeneration of dopaminergic cells to delay or prevent the development of Parkinson's disease.
-
Autores: Basaia, S.; Agosta, F.; Díez-Palacio, I.; et al.Revista: NEUROLOGYISSN: 0028-3878 Vol.98 N° 18 2022
-
Autores: Martin Bastida, Antonio; Delgado-Alvarado, M.; Navalpotro-Gómez, I.; et al.Revista: FRONTIERS IN NEUROLOGYISSN: 1664-2295 Vol.12 2021 págs. 733570ResumenDementia and mild forms of cognitive impairment as well as neuropsychiatric symptoms (i. e., impulse control disorders) are frequent and disabling non-motor symptoms of Parkinson's disease (PD). The identification of changes in neuroimaging studies for the early diagnosis and monitoring of the cognitive and neuropsychiatric symptoms associated with Parkinson's disease, as well as their pathophysiological understanding, are critical for the development of an optimal therapeutic approach. In the current literature review, we present an update on the latest structural and functional neuroimaging findings, including high magnetic field resonance and radionuclide imaging, assessing cognitive dysfunction and impulse control disorders in PD.
-
Autores: Ward, R. J.; Dexter, D. T.; Martin Bastida, Antonio; et al.Revista: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCESISSN: 1422-0067 Vol.22 N° 7 2021 págs. 3338ResumenIron loading in some brain regions occurs in Parkinson's Disease (PD), and it has been considered that its removal by iron chelators could be an appropriate therapeutic approach. Since neuroinflammation with microgliosis is also a common feature of PD, it is possible that iron is sequestered within cells as a result of the "anaemia of chronic disease" and remains unavailable to the chelator. In this review, the extent of neuroinflammation in PD is discussed together with the role played by glia cells, specifically microglia and astrocytes, in controlling iron metabolism during inflammation, together with the results of MRI studies. The current use of chelators in clinical medicine is presented together with a discussion of two clinical trials of PD patients where an iron chelator was administered and showed encouraging results. It is proposed that the use of anti-inflammatory drugs combined with an iron chelator might be a better approach to increase chelator efficacy.
-
Autores: Milán Tomás, Ángela; Fernández Matarrubia, Marta; Rodríguez Oroz, María Cruz (Autor de correspondencia)Revista: BEHAVIORAL SCIENCESISSN: 2076-328X Vol.11 N° 7 2021 págs. 94ResumenLewy body dementias (LBDs) consist of dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD), which are clinically similar syndromes that share neuropathological findings with widespread cortical Lewy body deposition, often with a variable degree of concomitant Alzheimer pathology. The objective of this article is to provide an overview of the neuropathological and clinical features, current diagnostic criteria, biomarkers, and management of LBD. Literature research was performed using the PubMed database, and the most pertinent articles were read and are discussed in this paper. The diagnostic criteria for DLB have recently been updated, with the addition of indicative and supportive biomarker information. The time interval of dementia onset relative to parkinsonism remains the major distinction between DLB and PDD, underpinning controversy about whether they are the same illness in a different spectrum of the disease or two separate neurodegenerative disorders. The treatment for LBD is only symptomatic, but the expected progression and prognosis differ between the two entities. Diagnosis in prodromal stages should be of the utmost importance, because implementing early treatment might change the course of the illness if disease-modifying therapies are developed in the future. Thus, the identification of novel biomarkers constitutes an area of active research, with a special focus on oc-synuclein markers.
-
Autores: Errea, O.; Rodríguez Oroz, María Cruz (Autor de correspondencia)Revista: MOVEMENT DISORDERSISSN: 0885-3185 Vol.36 N° 1 2021 págs. 83
-
Autores: Neumann, W. J. (Autor de correspondencia); Rodríguez Oroz, María CruzRevista: MOVEMENT DISORDERSISSN: 0885-3185 Vol.36 N° 4 2021 págs. 796 - 799
-
Autores: Martin Bastida, Antonio (Autor de correspondencia); Tilley, B. S. ; Bansal, S.; et al.Revista: JOURNAL OF NEURAL TRANSMISSIONISSN: 0300-9564 Vol.128 N° 1 2021 págs. 15 - 25ResumenIn these present studies, in vivo and and post-mortem studies have investigated the association between iron and inflammation. Early-stage Parkinson's disease (PD) patients, of less than 5 years disease duration, showed associations of plasmatic ferritin concentrations with both proinflammatory cytokine interleukin-6 and hepcidin, a regulator of iron metabolism as well as clinical measures. In addition ratios of plasmatic ferritin and iron accumulation in deep grey matter nuclei assessed with relaxometry T2* inversely correlated with disease severity and duration of PD. On the hand, post-mortem material of the substantia nigra compacta (SNc) divided according to Braak and Braak scores, III-IV and V-VI staging, exhibited comparable microgliosis, with a variety of phenotypes present. There was an association between the intensity of microgliosis and iron accumulation as assayed by Perl's staining in the SNc sections. In conclusion, markers of inflammation and iron metabolism in both systemic and brain systems are closely linked in PD, thus offering a potential biomarker for progression of the disease.
-
Autores: Gaig, C. (Autor de correspondencia); Compta, Y.; Heidbreder, A.; et al.Revista: NEUROLOGYISSN: 0028-3878 Vol.97 N° 14 2021 págs. E1367 - E1381ResumenBackground and Objectives Anti-IgLON5 disease is a recently described neurologic disease that shares features of autoimmunity and neurodegeneration. Abnormal movements appear to be frequent and important but have not been characterized and are underreported. We describe the frequency and types of movement disorders in a series of consecutive patients with this disease. Methods In this retrospective, observational study, the presence and phenomenology of movement disorders were assessed with a standardized clinical questionnaire. Available videos were centrally reviewed by 3 experts in movement disorders. Results Seventy-two patients were included. In 41 (57%), the main reason for initial consultation was difficulty walking along with one or several concurrent movement disorders. At the time of anti-IgLON5 diagnosis, 63 (87%) patients had at least 1 movement disorder with a median of 3 per patient. The most frequent abnormal movements were gait and balance disturbances (52 patients [72%]), chorea (24 [33%]), bradykinesia (20 [28%]), dystonia (19 [26%]), abnormal body postures or rigidity (18 [25%]), and tremor (15 [21%]). Other hyperkinetic movements (myoclonus, akathisia, myorhythmia, myokymia, or abdominal dyskinesias) occurred in 26 (36%) patients. The craniofacial region was one of the most frequently affected by multiple concurrent movement disorders (23 patients [32%]) including dystonia (13), myorhythmia (6), chorea (4), or myokymia (4). Considering any body region, the most frequent combination of multiple movement disorders consisted of gait instability or ataxia associated with craniofacial dyskinesias or generalized chorea observed in 31 (43%) patients. In addition to abnormal movements, 87% of patients had sleep alterations, 74% bulbar dysfunction, and 53% cognitive impairment. Fifty-five (76%) patients were treated with immunotherapy, resulting in important and sustained improvement of the movement disorders in only 7 (13%) cases. Discussion Movement disorders are a frequent and leading cause of initial neurologic consultation in patients with anti-IgLON5 disease. Although multiple types of abnormal movements can occur, the most prevalent are disorders of gait, generalized chorea, and dystonia and other dyskinesias that frequently affect craniofacial muscles. Overall, anti-IgLON5 disease should be considered in patients with multiple movement disorders, particularly if they occur in association with sleep alterations, bulbar dysfunction, or cognitive impairment.
-
Autores: Esteban-Peñalba, T.; Paz-Alonso, P. M.; Navalpotro-Gómez, I.; et al.Título: Functional correlates of response inhibition in impulse control disorders in Parkinson's diseaseRevista: NEUROIMAGE. CLINICALISSN: 2213-1582 Vol.32 2021 págs. 102822ResumenImpulse control disorder is a prevalent side-effect of Parkinson's disease (PD) medication, with a strong negative impact on the quality of life of those affected. Although impulsivity has classically been associated with response inhibition deficits, previous evidence from PD patients with impulse control disorder (ICD) has not revealed behavioral dysfunction in response inhibition. In this study, 18 PD patients with ICD, 17 PD patients without this complication, and 15 healthy controls performed a version of the conditional Stop Signal Task during functional magnetic resonance imaging. Whole-brain contrasts, regions of interest, and functional connectivity analyses were conducted. Our aim was to investigate the neural underpinnings of two aspects of response inhibition: proactive inhibition, inhibition that has been prepared beforehand, and restrained inhibition, inhibition of an invalid inhibitory tendency. We observed that, in respect to the other two groups, PD patients with ICD exhibited hyperactivation of the stopping network bilaterally while performing proactive inhibition. When engaged in restrained inhibition, they showed hyperactivation of the left inferior frontal gyrus, an area linked to action monitoring. Restrained inhibition also resulted in changes to the functional co-activation between inhibitory regions and left inferior parietal cortex and right supramarginal gyrus. Our findings indicate that PD patients with ICD completed the inhibition task correctly, showing altered engagement of inhibitory and attentional areas. During proactive inhibition they showed bilateral hyperactivation of two inhibitory regions, while during restrained inhibition they showed additional involvement of attentional areas responsible for alerting and orienting.
-
Autores: Parkin, B. L.; Daws, R. E.; Das-Neves, I.; et al.Revista: BRAIN COMMUNICATIONSISSN: 2632-1297 Vol.3 N° 3 2021 págs. fcab175ResumenThe cognitive deficits associated with Parkinson's disease vary across individuals and change across time, with implications for prognosis and treatment. Key outstanding challenges are to define the distinct behavioural characteristics of this disorder and develop diagnostic paradigms that can assess these sensitively in individuals. In a previous study, we measured different aspects of attentional control in Parkinson's disease using an established fMRI switching paradigm. We observed no deficits for the aspects of attention the task was designed to examine; instead those with Parkinson's disease learnt the operational requirements of the task more slowly. We hypothesized that a subset of people with early-to-mid stage Parkinson's might be impaired when encoding rules for performing new tasks. Here, we directly test this hypothesis and investigate whether deficits in instruction-based learning represent a characteristic of Parkinson's Disease. Seventeen participants with Parkinson's disease (8 male; mean age: 61.2 years), 18 older adults (8 male; mean age: 61.3 years) and 20 younger adults (10 males; mean age: 26.7 years) undertook a simple instruction-based learning paradigm in the MRI scanner. They sorted sequences of coloured shapes according to binary discrimination rules that were updated at two-minute intervals. Unlike common reinforcement learning tasks, the rules were unambiguous, being explicitly presented; consequently, there was no requirement to monitor feedback or estimate contingencies. Despite its simplicity, a third of the Parkinson's group, but only one older adult, showed marked increases in errors, 4 SD greater than the worst performing young adult. The pattern of errors was consistent, reflecting a tendency to misbind discrimination rules. The misbinding behaviour was coupled with reduced frontal, parietal and anterior caudate activity when rules were being encoded, but not when attention was initially oriented to the instruction slides or when discrimination trials were performed. Concomitantly, Magnetic Resonance Spectroscopy showed reduced gamma-Aminobutyric acid levels within the mid-dorsolateral prefrontal cortices of individuals who made misbinding errors. These results demonstrate, for the first time, that a subset of early-to-mid stage people with Parkinson's show substantial deficits when binding new task rules in working memory. Given the ubiquity of instruction-based learning, these deficits are likely to impede daily living. They will also confound clinical assessment of other cognitive processes. Future work should determine the value of instruction-based learning as a sensitive early marker of cognitive decline and as a measure of responsiveness to therapy in Parkinson's disease.
-
Autores: Hannaway, N.; Lao-Kaim, N. P.; Martin Bastida, Antonio; et al.Título: Longitudinal changes in movement-related functional MRI activity in Parkinson's disease patientsRevista: PARKINSONISM AND RELATED DISORDERSISSN: 1353-8020 Vol.87 2021 págs. 61 - 69ResumenIntroduction: Functional brain imaging has shown alterations in the basal ganglia, cortex and cerebellum in Parkinson's disease patients. However, few functional imaging studies have tested how these changes evolve over time. Our study aimed to test the longitudinal progression of movement-related functional activity in Parkinson's disease patients. Methods: At baseline, 48 Parkinson's disease patients and 16 healthy controls underwent structural and functional magnetic resonance imaging during a joystick motor task. Patients had repeated imaging after 18-months (n = 42) and 36-months (n = 32). T-tests compared functional responses between Parkinson's disease patients and controls, and linear mixed effects models examined longitudinal differences within Parkinson's disease. Correlations of motor-activity with bradykinesia, rigidity and tremor were undertaken. All contrasts used wholebrain analyses, thresholded at Z > 3.1 with a cluster-wise P < 0.05. Results: Baseline activation was significantly greater in patients than controls across contralateral parietal and occipital regions, ipsilateral precentral gyrus and thalamus. Longitudinally, patients showed significant increases in cerebellar activity at successive visits following baseline. Task-related activity also increased in the contralateral motor, parietal and temporal areas at 36 months compared to baseline, however this was reduced when controlling for motor task performance. Conclusion: We have shown that there are changes over time in the blood-activation level dependent response of patients with Parkinson's disease undertaking a simple motor task. These changes are observed primarily in the ipsilateral cerebellum and may be compensatory in nature.
-
Autores: Pagonabarraga, J. (Autor de correspondencia); Arbelo, J. M.; Grandas, F.; et al.Revista: BRAIN SCIENCESISSN: 2076-3425 Vol.10 N° 3 2020 págs. 176ResumenSafinamide is an approved drug for the treatment of motor fluctuations in Parkinson's disease (PD). Scarce data are available on its use in clinical practice. A group of Spanish movement disorders specialists was convened to review the use of safinamide across different clinical scenarios that may guide neurologists in clinical practice. Eight specialists with recognized expertise in PD management elaborated the statements based on available evidence in the literature and on their clinical experience. The RAND/UCLA method was carried, with final conclusions accepted after a 2-round modified Delphi process. Higher level of agreement between panellists was reached for the following statements. Safinamide significantly improves mean daily OFF time without troublesome dyskinesias. Adjunctive treatment with safinamide is associated with motor improvements in patients with mid-to-late PD. The efficacy of safinamide on motor fluctuations is maintained at long-term, with no increase over time in dyskinesias severity. The clinical benefits of safinamide on pain and depression remain unclear. Safinamide presents a similar incidence of adverse events compared with placebo. The efficacy and safety of safinamide shown in the pivotal clinical trials are reproduced in clinical practice, with improvement of parkinsonian symptoms, decrease of daily OFF time, control of dyskinesias at the long term, and good tolerability and safety.
-
Autores: Pagonabarraga, J. (Autor de correspondencia); Arbelo, J. M.; Grandas, F. ; et al.Revista: BRAIN SCIENCESISSN: 2076-3425 Vol.10 N° 5 2020 págs. 313
-
Autores: Navalpotro-Gómez, I.; Kim, J. ; Paz-Alonso, P. M.; et al.Título: Disrupted salience network dynamics in Parkinson's disease patients with impulse control disordersRevista: PARKINSONISM AND RELATED DISORDERSISSN: 1353-8020 Vol.70 2020 págs. 74 - 81ResumenBackground: Dynamic functional network analysis may add relevant information about the temporal nature of the neurocognitive alterations in PD patients with impulse control disorders (PD-ICD). Our aim was to investigate changes in dynamic functional network connectivity (dFNC) in PD-ICD patients, and topological properties of such networks. Methods: Resting state fMRI was performed on 16 PD PD-ICD patients, 20 PD patients without ICD and 17 healthy controls, whose demographic, clinical and behavioral scores were assessed. We conducted a group spatial independent component analysis, sliding window and graph-theory analyses. Results: PD-ICD patients, in contrast to PD-noICD and HC subjects, were engaged across time in a brain configuration pattern characterized by a lack of between-network connections at the expense of strong within-network connections (State III) in temporal, frontoinsular and cingulate cortices, all key nodes of the salience network. Moreover, this increased maintenance of State III in PD-ICD patients was positively correlated with the severity of impulsivity and novelty seeking as measured by specific scales. While in State III, these patients also exhibited increased local efficiency in all the aforementioned areas. Conclusions: Our findings show for the first time that PD-ICD patients have a dynamic functional engagement of local connectivity involving the limbic circuit, leading to the inefficient modulation in emotional processing and reward-related decision-making. These results provide new insights into the pathophysiology of ICD in PD padents and indicate that the dFC study of fMRI could be a useful biomarker to identify patients at risk to develop ICD.
-
Autores: Meles, S. K.; Renken, R. J.; Pagani, M.; et al.Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGINGISSN: 1619-7070 Vol.47 N° 2 2020 págs. 437 - 450ResumenRationale In Parkinson's disease (PD), spatial covariance analysis of F-18-FDG PET data has consistently revealed a characteristic PD-related brain pattern (PDRP). By quantifying PDRP expression on a scan-by-scan basis, this technique allows objective assessment of disease activity in individual subjects. We provide a further validation of the PDRP by applying spatial covariance analysis to PD cohorts from the Netherlands (NL), Italy (IT), and Spain (SP). Methods The PDRPNL was previously identified (17 controls, 19 PD) and its expression was determined in 19 healthy controls and 20 PD patients from the Netherlands. The PDRPIT was identified in 20 controls and 20 "de-novo" PD patients from an Italian cohort. A further 24 controls and 18 "de-novo" Italian patients were used for validation. The PDRPSP was identified in 19 controls and 19 PD patients from a Spanish cohort with late-stage PD. Thirty Spanish PD patients were used for validation. Patterns of the three centers were visually compared and then cross-validated. Furthermore, PDRP expression was determined in 8 patients with multiple system atrophy. Results A PDRP could be identified in each cohort. Each PDRP was characterized by relative hypermetabolism in the thalamus, putamen/pallidum, pons, cerebellum, and motor cortex. These changes co-varied with variable degrees of hypometabolism in posterior parietal, occipital, and frontal cortices. Frontal hypometabolism was less pronounced in "de-novo" PD subjects (Italian cohort). Occipital hypometabolism was more pronounced in late-stage PD subjects (Spanish cohort). PDRPIT, PDRPNL, and PDRPSP were significantly expressed in PD patients compared with controls in validation cohorts from the same center (P < 0.0001), and maintained significance on cross-validation (P < 0.005). PDRP expression was absent in MSA. Conclusion The PDRP is a reproducible disease characteristic across PD populations and scanning platforms globally. Further study is needed to identify the topography of specific PD subtypes, and to identify and correct for center-specific effects.
-
Autores: Rodríguez-Chinchilla, T.; Quiroga Varela, Ana; Molinet-Dronda, F.; et al.Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGINGISSN: 1619-7070 Vol.47 N° 11 2020 págs. 2602 - 2612
-
Autores: Jimenez-Urbieta, H.; Gago, B.; Quiroga Varela, Ana; et al.Revista: PSYCHOPHARMACOLOGYISSN: 0033-3158 Vol.237 N° 8 2020 págs. 2419 - 2431ResumenRationale Impulse control disorders (ICD) and other impulsive-compulsive behaviours are frequently found in Parkinson's disease (PD) patients treated with dopaminergic agonists. To date, there are no available animal models to investigate their pathophysiology and determine whether they can be elicited by varying doses of dopaminergic drugs. In addition, there is some controversy regarding the predispositional pattern of striatal dopaminergic depletion. Objectives To study the effect of two doses of pramipexole (PPX) on motor impulsivity, delay intolerance and compulsive-like behaviour. Methods Male rats with mild dopaminergic denervation in the dorsolateral striatum (bilateral injections of 6-hydroxidopamine (6-OHDA)) treated with two doses of PPX (0.25 mg/kg and 3 mg/kg) and tested in the variable delay-to-signal paradigm. Results Partial (50%) dopaminergic depletion did not induce significant changes in motor impulsivity or delay intolerance. However, 0.25 mg/kg of PPX increased motor impulsivity, while 3 mg/kg of PPX increased both motor impulsivity and delay intolerance. These effects were independent of the drug's antiparkinsonian effects. Importantly, impulsivity scores before and after dopaminergic lesion were positively associated with the impulsivity observed after administering 3 mg/kg of PPX. No compulsive-like behaviour was induced by PPX administration. Conclusions We described a rat model, with a moderate dorsolateral dopaminergic lesion resembling that suffered by patients with early PD, that develops different types of impulsivity in a dose-dependent manner dissociated from motor benefits when treated with PPX. This model recapitulates key features of abnormal impulsivity in PD and may be useful for deepening our understanding of the pathophysiology of ICD.
-
Autores: Li, WH. (Autor de correspondencia); Lao-Kaim, NP. ; Roussakis, A. A. ; et al.Título: Longitudinal functional connectivity changes related to dopaminergic decline in Parkinson's diseaseRevista: NEUROIMAGE. CLINICALISSN: 2213-1582 Vol.28 2020 págs. 102409ResumenBackground: Resting-state functional magnetic resonance imaging (fMRI) studies have demonstrated that basal ganglia functional connectivity is altered in Parkinson's disease (PD) as compared to healthy controls. However, such functional connectivity alterations have not been related to the dopaminergic deficits that occurs in PD over time. Objectives: To examine whether functional connectivity impairments are correlated with dopaminergic deficits across basal ganglia subdivisions in patients with PD both cross-sectionally and longitudinally. Methods: We assessed resting-state functional connectivity of basal ganglia subdivisions and dopamine transporter density using C-11-PE2I PET in thirty-four PD patients at baseline. Of these, twenty PD patients were rescanned after 19.9 +/- 3.8 months. A seed-based approach was used to analyze resting-state fMRI data. C-11-PE2I binding potential (BPND) was calculated for each participant. PD patients were assessed for disease severity. Results: At baseline, PD patients with greater dopaminergic deficits, as measured with C-11-PE2I PET, showed larger decreases in posterior putamen functional connectivity with the midbrain and pallidum. Reduced functional connectivity of the posterior putamen with the thalamus, midbrain, supplementary motor area and sensorimotor cortex over time were significantly associated with changes in DAT density over the same period. Furthermore, increased motor disability was associated with lower intraregional functional connectivity of the posterior putamen. Conclusions: Our findings suggest that basal ganglia functional connectivity is related to integrity of dopaminergic system in patients with PD. Application of resting-state fMRI in a large cohort and longitudinal scanning may be a powerful tool for assessing underlying PD pathology and its progression.
-
Autores: Paz-Alonso, P. M. (Autor de correspondencia); Navalpotro-Gomez, I. ; Boddy, P.; et al.Revista: MOVEMENT DISORDERSISSN: 0885-3185 Vol.35 N° 2 2020 págs. 316 - 325ResumenBACKGROUND: Impulse control disorders related to alterations in the mesocorticolimbic dopamine network occur in Parkinson's disease (PD). Our objective was to investigate the functional neural substrates of reward processing and inhibitory control in these patients. METHODS: Eighteen PD patients with impulse control disorders, 17 without this complication, and 18 healthy controls performed a version of the Iowa Gambling Task during functional magnetic resonance scanning under 3 conditions: positive, negative, and mixed feedback. Whole-brain contrasts, regions of interest, time courses, functional connectivity analyses, and brain-behavior associations were examined. RESULTS: PD patients with impulse control disorders exhibited hyperactivation in subcortical and cortical regions typically associated with reward processing and inhibitory control compared with their PD and healthy control counterparts. Time-course analyses revealed that only PD patients with impulse control disorders exhibited stronger signal intensity during the initial versus final periods of the negative-feedback condition in bilateral insula, and right ventral striatum. Interestingly, hyperactivation of all the examined right-lateralized frontostriatal areas during negative feedback was positively associated with impulse control disorder severity. Importantly, positive associations between impulse control disorder severity and regional activations in the right insula and right inferior frontal gyrus, but not the right subthalamic nucleus, were mediated by functional connectivity with the right ventral striatum. CONCLUSIONS: During a reward-based task, PD patients with impulse control disorders showed hyperactivation in a right-lateralized network of regions including the subthalamic nucleus that was strongly associated with impulse control disorder severity. In these patients, the right ventral striatum in particular played a critical role in modulating the functional dynamics of right-lateralized inhibitory-control frontal regions when facing penalties. © 2019 International Parkinson and Movement Disorder Society.
-
Autores: van Veen, R. (Autor de correspondencia); Gurvits, V.; Kogan, R. V.; et al.Revista: COMPUTER METHODS AND PROGRAMS IN BIOMEDICINEISSN: 0169-2607 Vol.197 2020 págs. 105708ResumenBackground and objective: Neurodegenerative diseases like Parkinson's disease often take several years before they can be diagnosed reliably based on clinical grounds. Imaging techniques such as MRI are used to detect anatomical (structural) pathological changes. However, these kinds of changes are usually seen only late in the development. The measurement of functional brain activity by means of [18F]fluorodeoxyglucose positron emission tomography (FDG-PET) can provide useful information, but its interpretation is more difficult. The scaled sub-profile model principal component analysis (SSM/PCA) was shown to provide more useful information than other statistical techniques. Our objective is to improve the performance further by combining SSM/PCA and prototype-based generalized matrix learning vector quantization (GMLVQ). Methods: We apply a combination of SSM/PCA and GMLVQ as a classifier. In order to demonstrate the combination's validity, we analyze FDG-PET data of Parkinson's disease (PD) patients collected at three different neuroimaging centers in Europe. We determine the diagnostic performance by performing a ten times repeated ten fold cross validation. Additionally, discriminant visualizations of the data are included. The prototypes and relevance of GMLVQ are transformed back to the original voxel space by exploiting the linearity of SSM/PCA. The resulting prototypes and relevance profiles have then been assessed by three neurologists. Results: One important finding is that discriminative visualization can help to identify disease-related properties as well as differences which are due to center-specific factors. Secondly, the neurologist assessed the interpretability of the method and confirmed that prototypes are similar to known activity profiles of PD patients. Conclusion: We have shown that the presented combination of SSM/PCA and GMLVQ can provide useful means to assess and better understand characteristic differences in FDG-PET data from PD patients and HCs. Based on the assessments by medical experts and the results of our computational analysis we conclude that the first steps towards a diagnostic support system have been taken successfully. Keywords: Parkinson¿s disease (PD); Scaled sub-profile scaling model principal component analysis (SSM/PCA); [(18)F]Fluorodeoxyglucose positron emission tomography (FDG-PET); generalized matrix learning vector quantization (GMLVQ).
-
Autores: Valentí Azcárate, Rafael; Martinez, I. ; Amat, I. ; et al.Revista: MOVEMENT DISORDERSISSN: 0885-3185 Vol.35 2020 págs. S372 - S372
-
Autores: Martí Andrés, Gloria María; Perovnik, M. ; Rebec, E.; et al.Revista: MOVEMENT DISORDERSISSN: 0885-3185 Vol.35 2020 págs. S114 - S116
-
Autores: Martínez Valbuena, Iván; Valentí Azcárate, Rafael; Caballero, C.; et al.Revista: MOVEMENT DISORDERSISSN: 0885-3185 Vol.35 N° SUPPL 1 2020 págs. S156 - S156
-
Autores: Martin Bastida, Antonio; Suárez Vega, Victor Manuel; Domínguez Echávarri, Pablo Daniel; et al.Título: Visualization of Nigrosome 1 at 3T MRI and 18F-DOPA PET for the diagnosis of Parkinson's diseaseRevista: MOVEMENT DISORDERSISSN: 0885-3185 Vol.35 2020 págs. S254 - S255
-
Autores: Armengou García, Laura; Martí Andrés, Gloria María; Valentí Azcárate, Rafael; et al.Revista: MOVEMENT DISORDERSISSN: 0885-3185 Vol.35 2020 págs. S436 - S437
-
Autores: Martin Bastida, Antonio; Delgado-Alvarado, M. ; Navalpotro-Gomez, I.; et al.Revista: MOVEMENT DISORDERSISSN: 0885-3185 Vol.35 N° Supl. 1 2020 págs. S254
-
Autores: Gasca Salas, Carmen; Garcia-Lorenzo, D.; García García, David; et al.Título: Parkinson's disease with mild cognitive impairment: severe cortical thinning antedates dementiaRevista: BRAIN IMAGING AND BEHAVIORISSN: 1931-7557 Vol.13 N° 1 2019 págs. 180 - 188ResumenMild cognitive impairment (MCI) in Parkinson's disease (PD) is a risk factor for dementia and thus, it is of interest to elucidate if specific patterns of atrophy in PD-MCI patients are associated with a higher risk of developing dementia. We aim to define pattern(s) of regional atrophy in PD-MCI patients who developed dementia during 31months of follow-up using cortical thickness analysis Twenty-three PD-MCI patients and 18 controls underwent brain MRI and completed a neuropsychological examination at baseline, PD-MCI patients were followed after a 31month follow-up in order to assess their progression to dementia. At follow up, 8 PD-MCI patients had converted to dementia (PD-MCI converters) whereas 15 remained as PD-MCI (PD-MCI non-converters). All patients were at least 60years old and suffered PD10years. There were no baseline differences between the two groups of patients in clinical and neuropsychological variables. The cortex of PD-MCI converters was thinner than that of PD-MCI non-converters, bilaterally in the frontal, insula and the left middle temporal areas, also displaying a more widespread pattern of cortical thinning relative to the controls. This study shows that aged and long-term PD patients with MCI who convert to dementia in the short-mid term suffer a thinning of the cortex in several areas (frontal cortex, and middle temporal lobe and insula), even when their cognitive impairment was similar to that of PD-MCI non-converters. Thus, MRI analysis of cortical thickness may represent a useful measure to identify PD-MCI patients at a higher risk of developing dementia.
-
Autores: Navalpotro-Gomez, I.; Dacosta-Aguayo, R.; Molinet-Dronda, F.; et al.Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGINGISSN: 1619-7070 Vol.46 N° 10 2019 págs. 2065 - 2076ResumenPurposePrevious studies in patients with Parkinson's disease (PD) and impulse control disorders (ICDs) have produced heterogeneous results regarding striatal dopamine transporter (DaT) binding and activity in the mesocorticolimbic network. Our aim here was to study the relationship between striatal DaT availability and cortical metabolism, as well as motor, behavioural and cognitive features of PD patients with ICD.MethodsIn a group of PD patients with ICD (PD-ICD, n=16) and 16 matched PD patients without ICD (PD-noICD, n=16), DaT single-photon emission computed tomography (SPECT) imaging (DaTSCAN) was used to study DaT availability in predefined striatal volumes of interest (VOIs): putamen, caudate nucleus and ventral striatum (VS). In addition, the specific association of striatal DaT binding with cortical limbic and associative metabolic activity was evaluated by F-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) in PD-ICD patients and investigated using statistical parametric mapping (SPM8). Finally, associations between DaT availability and motor, behavioural and cognitive features were assessed.ResultsPD-ICD patients had a significantly lower DaT density in the VS than PD-noICD patients, which was inversely associated with ICD severity. Lower DaT availability in the VS was associated with lower FDG uptake in several cortical areas belonging to the limbic and associative circuits, and in other regions involved in reward and inhibition processes (p<0.0001 uncorrected; k>50 voxels). No significant results were observed using a higher conservative threshold (p<0.05; FDR corrected). PD-ICD patients also displayed impairment in interference and attentional Stroop Task execution, and more anxiety, all associated with reduced DaT availability in the VS and caudate nucleus.ConclusionsICDs in PD patients are related to reduced DaT binding in the VS, which accounts for dysfunction in a complex cortico-subcortical network that involves areas of the mesolimbic and mesocortical systems, being associated with reward evaluation, salience attribution and inhibitory control processes.
-
Autores: de Iure A; Napolitano F; Beck G; et al.Revista: MOVEMENT DISORDERSISSN: 0885-3185 Vol.34 N° 6 2019 págs. 832 - 844
-
Autores: Jimenez-Urbieta, H.; Gago, B. ; Quiroga Varela, Ana; et al.Revista: NEUROBIOLOGY OF AGINGISSN: 0197-4580 Vol.75 2019 págs. 126 - 135ResumenTreatment with dopaminergic agonists such as pramipexole (PPX) contributes to the development of impulse control disorders (ICDs) in patients with Parkinson's disease (PD). As such, animal models of abnormal impulse control in PD are needed to better study the pathophysiology of these behaviors. Thus, we investigated impulsivity and related behaviors using the 5-choice serial reaction time task, as well as FosB/Delta FosB expression, in rats with mild parkinsonism induced by viral-mediated substantia nigra overexpression of human A53T mutated alpha-synuclein, and following chronic PPX treatment (0.25 mg/kg/d) for 4 weeks. The bilateral loss of striatal dopamine transporters (64%) increased the premature response rate of these rats, indicating enhanced waiting impulsivity. This behavior persisted in the OFF state after the second week of PPX treatment and it was further exacerbated in the ON state throughout the treatment period. The enhanced rate of premature responses following dopaminergic denervation was positively correlated with the premature response rate following PPX treatment (both in the ON and OFF states). Moreover, the striatal dopaminergic deficit was negatively correlated with the premature response rate at all times (pretreatment, ON and OFF states) and it was positively correlated with the striatal FosB/Delta FosB expression. By contrast, PPX treatment was not associated with changes in compulsivity (perseverative responses rate). This model recapitulates some features of PD with ICD, namely the dopaminergic deficit of early PD and the impulsivity traits provoked by dopaminergic loss in association with PPX treatment, making this model a useful tool to study the pathophysiology of ICDs. (C) 2018 Elsevier Inc. All rights reserved.
-
Autores: Durante V.; De Iure A.; Loffredo V.; et al.Revista: BRAINISSN: 0006-8950 Vol.142 N° 5 2019 págs. 1365 - 1385
-
Autores: Martin Bastida, Antonio; Lao-Kaim, N. R.; Roussakis, A. A.; et al.Título: Relationship between neuromelanin and dopamine terminals within the Parkinson's nigrostriatal systemRevista: BRAINISSN: 0006-8950 Vol.142 2019 págs. 2023 - 2036ResumenParkinson's disease is characterized by the progressive loss of pigmented dopaminergic neurons in the substantia nigra and associated striatal deafferentation. Neuromelanin content is thought to reflect the loss of pigmented neurons, but available data characterizing its relationship with striatal dopaminergic integrity are not comprehensive or consistent, and predominantly involve heterogeneous samples. In this cross-sectional study, we used neuromelanin-sensitive MRI and the highly specific dopamine transporter PET radioligand, C-11-PE2I, to assess the association between neuromelanin-containing cell levels in the substantia nigra pars compacta and nigrostriatal terminal density in vivo, in 30 patients with bilateral Parkinson's disease. Fifteen healthy control subjects also underwent neuromelanin-sensitive imaging. We used a novel approach taking into account the anatomical and functional subdivision of substantia nigra into dorsal and ventral tiers and striatal nuclei into pre- and post-commissural subregions, in accordance with previous animal and post-mortem studies, and consider the clinically asymmetric disease presentation. In vivo, Parkinson's disease subjects displayed reduced neuromelanin levels in the ventral (-30 +/- 28%) and dorsal tiers (-21 +/- 24%) as compared to the control group [F(1,43) = 11.95, P = 0.001]. Within the Parkinson's disease group, nigral pigmentation was lower in the ventral tier as compared to the dorsal tier [F(1,29) = 36.19, P < 0.001] and lower in the clinically-defined most affected side [F(1,29) = 4.85, P = 0.036]. Similarly, lower dopamine transporter density was observed in the ventral tier [F(1,29) = 76.39, P < 0.001] and clinically-defined most affected side [F(1,29) = 4.21, P = 0.049]. Despite similar patterns, regression analysis showed no significant association between nigral pigmentation and nigral dopamine transporter density. However, for the clinically-defined most affected side, significant relationships were observed between pigmentation of the ventral nigral tier with striatal dopamine transporter binding in pre-commissural and post-commissural striatal subregions known to receive nigrostriatal projections from this tier, while the dorsal tier correlated with striatal projection sites in the pre-commissural striatum (P < 0.05, Benjamini-Hochberg corrected). In contrast, there were no statistically significant relationships between these two measures in the clinically-defined least affected side. These findings provide important insights into the topography of nigrostriatal neurodegeneration in Parkinson's disease, indicating that the characteristics of disease progression may fundamentally differ across hemispheres and support post-mortem data showing asynchrony in the loss of neuromelanin-containing versus tyrosine hydroxylase positive nigral cells.
-
Autores: Garcia-Ruiz, P. J.; Sanz-Cartagena, P. (Autor de correspondencia); Martinez-Castrillo, J. C.; et al.Revista: REVISTA DE NEUROLOGIAISSN: 0210-0010 Vol.66 N° 5 2018 págs. 163 - 172ResumenIntroduction. Botulinum toxin type A (BTA) is a bacterial endotoxin, whose therapeutic use has had a dramatic impact on different neurological disorders, such as dystonia and spasticity. Aim. To analyze and summarize different questions about the use of BTA in our clinical practice. Development. A group of experts in neurology developed a list of topics related with the use of BTA. Two groups were considered: neuropharmacology and dystonia. A literature search at PubMed, mainly for English language articles published up to June 2016 was performed. The manuscript was structured as a questionnaire that includes those questions that, according to the panel opinion, could generate more controversy or doubt. The initial draft was reviewed by the expert panel members to allow modifications, and after subsequent revisions for achieving the highest degree of consensus, the final text was then validated. Different questions about diverse aspects of neuropharmacology, such as mechanism of action, bioequivalence of the different preparations, immunogenicity, etc. were included. Regarding dystonia, the document included questions about methods of evaluation, cervical dystonia, blepharospasm, etc. Conclusion. This review does not pretend to be a guide, but rather a tool for continuous training of residents and specialists in neurology, about different specific areas of the management of BTA.
-
Autores: Dranca, L. ; de Mendarozketa, L. D. R.; Goñi, A.; et al.Revista: BMC BIOINFORMATICSISSN: 1471-2105 Vol.19 N° 1 2018 págs. 471ResumenBackgroundParkinson's Disease (PD) is a chronic neurodegenerative disease associated with motor problems such as gait impairment. Different systems based on 3D cameras, accelerometers or gyroscopes have been used in related works in order to study gait disturbances in PD. Kinect (?) has also been used to build these kinds of systems, but contradictory results have been reported: some works conclude that Kinect does not provide an accurate method of measuring gait kinematics variables, but others, on the contrary, report good accuracy results.MethodsIn this work, we have built a Kinect-based system that can distinguish between different PD stages, and have performed a clinical study with 30 patients suffering from PD belonging to three groups: early PD patients without axial impairment, more evolved PD patients with higher gait impairment but without Freezing of Gait (FoG), and patients with advanced PD and FoG. Those patients were recorded by two Kinect devices when they were walking in a hospital corridor. The datasets obtained from the Kinect were preprocessed, 115 features identified, some methods were applied to select the relevant features (correlation based feature selection, information gain, and consistency subset evaluation), and different classification methods (decision trees, Bayesian networks, neural networks and K-nearest neighbours classifiers) were evaluated with the goal of finding the most accurate method for PD stage classification.ResultsThe classifier that provided the best results is a particular case of a Bayesian Network classifier (similar to a Naive Bayesian classifier) built from a set of 7 relevant features selected by the correlation-based on feature selection method. The accuracy obtained for that classifier using 10-fold cross validation is 93.40%. The relevant features are related to left shin angles, left humerus angles, frontal and lateral bents, left forearm angles and the number of steps during spin.ConclusionsIn this paper, it is shown that using Kinect is adequate to build a inexpensive and comfortable system that classifies PD into three different stages related to FoG. Compared to the results of previous works, the obtained accuracy (93.40%) can be considered high. The relevant features for the classifier are: a) movement and position of the left arm, b) trunk position for slightly displaced walking sequences, and c) left shin angle, for straight walking sequences. However, we have obtained a better accuracy (96.23%) for a classifier that only uses features extracted from slightly displaced walking steps and spin walking steps. Finally, the obtained set of relevant features may lead to new rehabilitation therapies for PD patients with gait problems.
-
Autores: Viedma-Guiard, E.; Aguero, P.; Crespo-Araico, L.; et al.Revista: NEUROLOGIAISSN: 1578-1968 Vol.33 N° 2 2018 págs. 107-111ResumenImplementing an e-mail-based consultation system is feasible in MD units. It facilitates both communication between neurologists and patients and continued care in the primary care setting.
-
Autores: Delgado-Alvarado, M.; Dacosta-Aguayo, R.; Navalpotro-Gomez, I.; et al.Revista: MOVEMENT DISORDERSISSN: 0885-3185 Vol.33 N° 11 2018 págs. 1809 - 1814ResumenBackground: There is a need for biomarkers of dementia in PD. Objectives: To determine if the levels of the main CSF proteins and their ratios are associated with deterioration in cognition and progression to dementia in the short to mid term. Methods: The Parkinson's Progression Markers Initiative database was used as an exploratory cohort, and a center-based cohort was used as a replication cohort. Amyloid ss 1-42, total tau, threonine-181 phosphorylated tau, and alpha-synuclein in the CSF and the ratios of these proteins were assessed. Results: In the Parkinson's Progression Markers Initiative cohort (n = 281), the total tau/amyloid ss 1-42, total tau/alpha-synuclein, total tau/amyloid ss 1-42+alpha-synuclein, and amyloid ss 1-42/total tau ratios were associated with a risk of progression to dementia over a 3-year follow-up. In the replication cohort (n = 40), the total tau/alpha-synuclein and total tau/amyloid ss 1-42+alpha-synuclein ratios were associated with progression to dementia over a 41-month follow-up. Conclusion: Ratios of the main proteins found in PD patient brain inclusions that can be measured in the CSF appear to have value as short- to mid-term predictors of dementia. (c) 2018 International Parkinson and Movement Disorder Society
Proyectos desde 2018
-
Título: 0011-4001-2023-000028 Modelos predictivos de enfermedades neurodegenerativasCódigo de expediente: 0011-4001-2023-000028Investigador principal: MARIA CRUZ RODRIGUEZ OROZ.Financiador: GOBIERNO DE NAVARRAConvocatoria: 2023 GN InvestigoFecha de inicio: 05-07-2023Fecha fin: 04-07-2024Importe concedido: 33.003,92€Otros fondos: Fondos MRR
-
Título: INNOLFACT 2.0: Combinación de Inteligencia Artificial y Reposicionamiento de Fármacos en Medicina de Precisión OlfatoriaCódigo de expediente: 0011-1411-2023-000100Investigador principal: MARIA CRUZ RODRIGUEZ OROZ.Financiador: GOBIERNO DE NAVARRAConvocatoria: 2023 GN PROYECTOS ESTRATEGICOS DE I+D 2023-2026Fecha de inicio: 01-07-2023Fecha fin: 31-12-2025Importe concedido: 331.400,55€Otros fondos: -
-
Título: RodríguezOroz_GN2022/28_Restauración de la función sináptica en el estado premotor de la enfermedad de Parkinson mediantemodulación proteica con terapia génica y terapias molecularesCódigo de expediente: GN2022/28Investigador principal: MARIA CRUZ RODRIGUEZ OROZ.Financiador: GOBIERNO DE NAVARRA. DEPARTAMENTO DE SALUDConvocatoria: 2022 GN Proyectos de Investigación en saludFecha de inicio: 22-12-2022Fecha fin: 21-12-2025Importe concedido: 79.349,14€Otros fondos: -
-
Título: 0011-4001-2022-000042 Gn_Investigo_2021Código de expediente: 0011-4001-2022-000042Investigador principal: MARIA CRUZ RODRIGUEZ OROZ.Financiador: GOBIERNO DE NAVARRAConvocatoria: 2021 GN InvestigoFecha de inicio: 18-11-2022Fecha fin: 17-11-2023Importe concedido: 33.108,92€Otros fondos: Fondos MRR
-
Título: 0011-4001-2022-000001 Programa Investigo de Gobierno de Navarra 2021Código de expediente: 0011-4001-2022-000001Investigador principal: MARIA CRUZ RODRIGUEZ OROZ, MARIA CRUZ RODRIGUEZ OROZ.Financiador: GOBIERNO DE NAVARRAConvocatoria: 2021 GN InvestigoFecha de inicio: 14-03-2022Fecha fin: 13-03-2023Importe concedido: 33.108,92€Otros fondos: Fondos MRR
-
Título: INNOLFACT: Implementación de Medicina de Precisión Olfatoria y Desarrollo de terapias nasalesCódigo de expediente: 0011-1411-2020-000036Investigador principal: MARIA CRUZ RODRIGUEZ OROZ, MARIA CRUZ RODRIGUEZ OROZ.Financiador: GOBIERNO DE NAVARRAConvocatoria: 2020 GN PROYECTOS ESTRATEGICOS DE I+D 2020-2022Fecha de inicio: 01-07-2020Fecha fin: 30-11-2022Importe concedido: 601.228,00€Otros fondos: -
-
Título: Desarrollo de terapias nasales inmunomoduladoras en envejecimiento y neurodegeneración (INNOLFACT)Código de expediente: 0011-1411-2020-000049Investigador principal: JUAN JOSE LASARTE SAGASTIBELZA.Financiador: GOBIERNO DE NAVARRAConvocatoria: FIMA 2020 GN PROYECTOS ESTRATEGICOS DE I+D 2020-2022Fecha de inicio: 01-07-2020Fecha fin: 30-11-2022Importe concedido: 399.103,16€Otros fondos: -
-
Título: Alteraciones de la sinapsis en el estriado y en la corteza frontal en la disfunción ejecutiva de la enfermedad de ParkinsonCódigo de expediente: PI19/01915Investigador principal: MARIA CRUZ RODRIGUEZ OROZ, MARIA CRUZ RODRIGUEZ OROZ.Financiador: INSTITUTO DE SALUD CARLOS IIIConvocatoria: 2019 AES Proyectos de investigaciónFecha de inicio: 01-01-2020Fecha fin: 30-06-2024Importe concedido: 123.420,00€Otros fondos: Fondos FEDER
-
Título: Implantación del diagnóstico de la epilepsia y la migraña en Navarra (Geneurona)Código de expediente: 0011-1411-2018-000053Investigador principal: MARIA CRUZ RODRIGUEZ OROZ, MARIA CRUZ RODRIGUEZ OROZ.Financiador: GOBIERNO DE NAVARRAConvocatoria: 2018 GN PROYECTOS ESTRATEGICOS DE I+D 2018-2020Fecha de inicio: 01-04-2018Fecha fin: 30-11-2020Importe concedido: 18.481,69€Otros fondos: -
-
Título: GENEURONA. Implantación del diagnóstico genómico de la epilepsia y la migraña en NavarraCódigo de expediente: 0011-1411-2018-000044Investigador principal: ANA MARIA GARCIA OSTA, ANA MARIA GARCIA OSTA.Financiador: GOBIERNO DE NAVARRAConvocatoria: 2018- GN PROY. ESTRATEGICOS DE I+D 2018-2020Fecha de inicio: 01-04-2018Fecha fin: 30-11-2020Importe concedido: 476.239,53€Otros fondos: -
-
Título: GOB. VASCO PREDOCTORAL Arantzazu Bellosos (MCRO)Código de expediente:Investigador principal: ARANTZAZU BELLOSO IGUERATEGUI, ARANTZAZU BELLOSO IGUERATEGUI.Financiador: GOBIERNO VASCOConvocatoria: 2016 - GV PREDOCTORAL FIMA 2019 - GV PREDOCTORAL FIMA 2019 - GV PREDOCTORAL 2018 - GV PREDOCTORALFecha de inicio: 07-02-2018Fecha fin: 31-12-2020Importe concedido: 66.979,16€Otros fondos: -
-
Título: Evaluación mediante RMN de pacientes tratados mediante talatInvestigador principal: MARIA CRUZ RODRIGUEZ OROZFecha de inicio: 13-02-2020Fecha fin: 30-10-2023Importe: 0Otros fondos: -
-
Título: Directional stimulation of the subthalamic nucleus.ParkinsonInvestigador principal: MARIA CRUZ RODRIGUEZ OROZFecha de inicio: 01-09-2019Fecha fin: 15-09-2022Importe: 0Otros fondos: -